The Quality Lowdown: COVID-19's Pressures On Drug Quality
Demand surges, supply surges and investigator travel restrictions are forcing FDA to adopt less restrictive regulatory approaches during the pandemic.
You may also be interested in...
The Quality Lowdown: Yes, The US FDA Expects You To Heed Import Alerts And Testing Requirements
PCCA repackaged adulterated APIs, Allay failed to understand processes, ShangRao and Mexican firms peddled subpotent, sometimes methanol-tainted ethanol.
Chinese Firm Hit With Pandemic's First Remote-Records-Based FDA Drug GMP Warning Letter
Import alert and warning letter came after Ningbo, China, over-the-counter skin care products firm failed to share requested testing records.
Pandemic Will Continue Limiting US FDA Inspections In Driving FY 2021 Drug GMP Warnings
FDA historically has based 100% of drug adulteration warning letters on inspections but COVID-19-related travel restrictions began changing that in FY 2020, when 2% of drug GMP warning letters were based on testing import samples. The change became even more pronounced in the first two months of FY 2021, with 59% of actions related to sample testing and 41% to inspections.